Skip to Content
Søg Menu

Trodelvy (sacituzumab govitecan) – A new effective treatment option for breast cancer

Data presented at SABCS22 shows that Trodelvy, sacituzumab govitecan, is an effective new treatment option for patients with pre-treated, endocrine-resistant HR+/HER2- metastatic breast cancer.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Nordic Collaboration on Breast Cancer Research Reignited

/ BestPractice Nordic
Brystcancer
Louise Wichmann Matthiessen

Nye positive resultater for behandling af brystcancer fremlagt på ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video 03:02
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
ESMO24Brystcancer Play the Video 04:50
Bjørn Naume

Flere behandlingsmuligheter nå enn før for HER2-lav brystkreft

/ Bjørn Naume
Brystcancer Play the Video 1:40
Bjørn Naume

Nye behandlingstilbud for HER2-lav brystkreft

/ Bjørn Naume
Brystcancer Play the Video 07:08
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
ESMO24Brystcancer Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
ESMO24Brystcancer Play the Video 1:23

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
ESMO24Brystcancer

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
ESMO24Brystcancer

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top